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Adherence to medical therapies is a growing issue, so much so that the World Health Organization defined it as “a
new pharmacological problem”. The main factors affecting compliance are: frequency of administration, rapid onset
of action, role of device. The most severe consequence of non-adherence is the increased risk of poor clinical outcome,
associated with worsening of the quality of life and increase in health-care expenditure. It appears crucial to identify
those COPD patients who are “poorly or not at all compliant with their treatment”. In order to evaluate adherence to
the medical therapy, several methods were proposed, the most effective of which turned out to be self-reports,
i.e. simple, brief questionnaires (e.g. Morisky test). To increase the likelihood of quickly identifying non-compliant
patients, it may be useful to administer a simple questionnaire to naïve subjects (for example, in the waiting
room before an examination) including six specific items allowing to identify the patient’s key characteristics.
Depending on the answers, patients who do not comply with their pharmacological treatment may be classified
as belonging to 6 phenotypes. For patients who are already under treatment it might be useful to administer
another short questionnaire during follow up examination. Once the risk of non-compliance is identified, four
possible types of measures can be taken: prescription-related, educational, behavioral and complex combined
measures (combination of two or more actions).
Therefore, while it is clear that adherence in COPD is a critical issue, it is also obvious that raising awareness on
the disease and improving cooperation among specialists, general practitioners, health-care professionals, and
patients is the starting point at which this evolution should immediately begin. Each medication is able to foster
good compliance with the therapy, and consequently to maximize the efficacy, by virtue of its specific inhaler
and its own active ingredient.
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“Drugs don’t work in patients who don’t take them”.
This quote by C. Everett Koop is not so obvious as it
might seem. As a matter of fact, in order for a drug to
have a therapeutic effect, not only the active ingredient
should be effective and the carrier delivering it to the
body be optimal, but, most importantly, the patient must
adhere to the therapy [1].
The term “compliance “has been used to assess a treat-
ment regimen and the following passive behavior from the
patient respect to specific prescription like an acquiescent
recipient of expert medical prescription.* Correspondence: sanduzzi@unina.it
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unless otherwise stated.The accurate definition instead of “adherence” considers
the approval and “active” leading part of the patient in his
own health management. The latter term of adherence
more accurately reflects a patient’ s active role in consent-
ing and following prescribed treatments [2].
Most recently the term “concordance” has been used to
describe the “therapeutic alliance” that exists between
patients and medical healthcare professionals. In sum,
the compliance is a patient’s behavior versus therapeutic
prescription; whereas adherence: the patient’s behavior
after approval prescription and concordance is the rela-
tionship doctor-patient versus agreed decision. Another
word has been recently added to the two mentioned
above, namely “agreement”, which indicates a medical
treatment prescription model based on negotiation and
agreement by and between the physician and the patient,
reflecting and valuing the viewpoint of the latter.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In a recent survey carried out with pulmunologists, the
definition of adherence in Respiratory Medicine that has
received the highest consensus has been the following:
“A condition that can only be fulfilled when the patient
accepts the presence of the disease and the issues related
to the recommended therapy” [3].
Intentional non adherence is an active decision taken by
patients who fail to fill prescribed therapy. Approximately
15% of patients do not fill a new prescription and generally
discontinue therapy after about six months.
Unintentional non-adherence, instead, could be consid-
ered a passive process; the patients fail to adhere to pre-
scribing instructions for many reasons out of their control
(old age, social conditions etc.,). Prevalence estimates of
unintentional non-adherence vary considerably, but this
condition is more frequent with a range from 20% to over
50%. Although it has been documented that patients
exhibit both intentional and unintentional non-adherence,
no previous study has explored the interrelationship be-
tween unintentional and intentional non-adherence in
relation to patients’ medication beliefs [4].
Regardless of the language used, it is unquestionable
that the full benefits of a therapy can only be reaped if the
patient complies as closely as possible with the physician’s
prescription.
Methodological remarks
This paper is the result of the work carried out by a team
of 10 experts focusing on Chronic Obstructive Pulmonary
Disease (COPD) who developed evaluations and sug-
gestions on inhaled therapies. These experts held several
meetings in 2013 in order to discuss the critical issues
relating to the administration of inhaled drugs and to the
use of the required inhalers.
Throughout the process, the literature available on this
topic was examined (over 50 peer-reviewed articles and
reviews) [1-38] before the resulting document was dis-
cussed and approved in its final version. Then, two ques-
tionnaires were developed in order to assess the risk of
poor compliance by COPD patients, both naïve patients
and patients who were already under inhaled therapy.
The distinctive feature of this work was the observation
of real-life scenarios aimed at deriving indications for the
application of patient-centered medicine.
The Team hopes that such observations will generate
stimuli to develop experiences aimed at validating the
above-mentioned questionnaires and then implementing
them as part of good clinical practice.
Adherence: an increasingly serious issue
Adherence to medical therapies is a growing issue, so
much so that the World Health Organization (WHO),
through Mr. Clancy (Director of the Agency for HealthResearch and Quality) defined it as “a new pharmacological
problem”.
This statement is particularly true if one considers the
extent to which non-compliance with a medical therapy
may affect the efficacy of a drug also in terms of survival.
Some studies even showed that a patient who regularly
takes a placebo is more likely to survive than a patient
showing poor compliance with a pharmacological therapy
[5]. According to the WHO, “maximizing the effectiveness
of investments aimed at increasing compliance may have
a far better impact on people’s health than any other
progress in the therapeutic arena”.
A possible explanation of this unexpected phenomenon
could be found in the identification of a “compliant
phenotype,” i.e. a person who is more aware of the available
health indicators, who takes better care of himself/herself,
and follows more closely the therapeutic recommendations
given to him/her [6].
Shifting the focus onto COPD, what can be inferred is
that, despite the severity of this medical condition, the
level of compliance is very low, lower than the compliance
rate recorded for other diseases (Figure 1) [1].
In real-life conditions, the percentage of compliant
patients is much lower (10-40%) than the percentages
reported in the literature (40-60%) [7,8], and those
recorded in clinical trials (70-90%) [9,10].
Data from a recent Educational Program to stop smok-
ing by the Italian Society of Respiratory Medicine show
that the major difficulties are related to the requirement
to stop smoking. Unless the patient understands that the
first thing to do is to quit smoking, he/she will not under-
stand the importance of strictly following the prescribed
medication dosage. Based on the estimates published in a
recent DOXA survey, ordered by the three scientific soci-
eties SIMER-SIAIC-AAITO, Italy shows some worrying
figures. Out of a roughly estimated seven million patients
suffering from COPD and asthma (prevalence of 6.2%
for asthma and of 5.3% for COPD), 1,000,000 never
used spray inhalers, 1,300,000 stopped using them, and
2,700,000 use them “intermittently”, namely as an emer-
gency therapy. On top of this, considering that approxi-
mately 300,000 newly diagnosed patients add up to the
total amount every year, with an estimated mortality rate
of approximately 40,000 patients per year, one can fully
understand the extent of the problem [11].
Causes of non-compliance
Poor compliance with the medical therapy is character-
ized by a predisposition to unhealthy behaviors and life-
styles and is associated with several factors, which can
be correlated with the prescribed medications (number
of medications to be taken, difficulties in handling the de-
vice, complex regimes, side effects, cost of medications…)
or with other causes (old age, physical and cognitive
Figure 1 Distribution of medication possession ratios (MPR) for eight medical conditions among 15,334 patients (the areas of the circles
are proportional to the sample sizes. Median MPR is represented by horizontal bars). Mod. from [9].
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or understood, poor trust in the therapies and/or in the
physician, weak will, fears or unexpressed problems,
underestimation of the severity of the disease, lack of
symptoms) [12].
The most common type of non-adherence in COPD pa-
tients is underuse and improper use in the most frequent
type of non-adherence in patients older than 65 years of
age with polypharmacy. The older patients have multiple
comorbidities (diabetes, chronic ischemic heart disease,
depression, systemic hypertension) and they have to at-
tend a lot of therapeutic prescriptions. Forgetfulness
probably is the most common unintentional behavior to
skip doses in order to make the medication last longer.
The attitude towards inhaled medications in the elderly
patients is influenced by a great diversity of factors. The
reasons for non-adherence in the older-aged include items
related to the medicine (e.g. cost, number of medicines,
adverse effects) and those related to the person (e.g. de-
pression) [13]. However, many patients cannot use inhalers
correctly, and over 50% of patients struggle to use a
metered-dose inhaler properly. Poor inhaler technique
is associated with a reduced control, and worst COPD
outcomes. A lack of perceived benefit led to 30% of pa-
tients with COPD intentionally discontinuing their ther-
apy [14]. Training patients and caregivers in the correct
inhaler preparation and use is an essential component in
the process toward achieving reliable and repeatable medi-
cation delivery. Instructions should be inhaler-specific,
and they should include instruction on how to load or
prime the device [15].
The WHO grouped these multiple causes of non-
compliance into 5 dimensions, i.e. socio-economic, therapy-
related, patient-related, disease-related, related to the
health-care system or to the medical team [9].The main factors preventing good compliance include:
the patients’ cultural level, psychological issues, insufficient
amount of information given at the time of prescription
as to the pursued purpose and therapeutic goals, and,
most importantly, comorbidities. Indeed, together with
the treatment complexity, comorbidities have a bigger
negative impact on compliance rather than adverse events
[16]. It should be pointed out that, among comorbidities,
a major role is played by depression, which affects 10%
to 42% of stable COPD patients. A recent study carried
out on almost 75,000 patients shows that depression is
strongly correlated to the discontinuation of a therapy
and to the decrease in the number of days the medica-
tion is actually taken by the patient. Hence, the need to
promptly start treating this medical condition, before it
seriously affects the efficacy of the treatment [17].
However, the Global Initiative on Obstructive Lung
Disease (GOLD) recommends that patients with COPD
should be referred for pulmonary rehabilitation once their
FEV1 falls below normal level. Poor patient participation
and adherence are the lowest to referring patients with a
forced expiratory volume in one second (FEV1) < 80% pre-
dicted to pulmonary rehabilitation (5%) [18].
Factors affecting compliance
1) Frequency of administration
One of the key factors for achieving good compliance
is the number of daily administrations. It is actually
well known that the higher is the number of
administrations, the lower the adherence to the
medical therapy. The percentage of compliant COPD
patients drops from 43% with a once daily medication
to 23% with a therapy requiring 4 administrations per
day (Figure 2) [19].
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Figure 2 Percentage of days under treatment as a function of the number of daily administrations in patients with chronic obstructive
pulmonary disease. Mod. from [19].
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onto the market is to be viewed as a very positive
development. Among the active ingredients that are
currently available, indacaterol, glycopyrronium, and
tiotropium administered in once daily doses showed
an actual 24-hour coverage thanks to their long
action, while formetorol, salmetorol, and aclidinium
are to be administered twice daily (12 hour coverage
only). Looking at the molecules that are currently in
the pipeline and will be available in the near future,
what can be inferred is that most of them shall come
in once daily dosage. The molecules that will become
available for use in clinical practice are: Olodaterol,
Vilanterol, and Umeclidinium, to be administered as
monotherapies, and Indacaterol/Glicopirronium,
Vilanterol/Umeclidinium, Olodaterol/Tiotropium, to
be administered as combination therapies for the
treatment of COPD patients (Table 1).
2) Rapid onset of action
The fast action of a pharmaceutical product can be
seen as one of the factors that affect adherence to a
medical therapy. It is believed that the perception of
the product delivering its action rapidly may lead the
patient to continue taking the therapy on a daily basis.
Among the products that are currently available,
indacaterol, glycopyrronium, and formoterol are fast
acting (action starts within 5 minutes), whileble 1 COPD medications subdivided on the basis of the num
LABA LAMA
nce daily Indacaterol Tiotropium
Olodaterol Glicopirronium
Vilanterol Umeclidinium
ice daily Formaterol Aclidinium
Salmeterol
bold, products currently available on the market. In italics, products that will be matiotropium, aclidinium, and salmeterol act in
approximately 30 minutes [20].
3) The role of device
Another key factor that is closely related to the
patients’ compliance with their medical therapy is
the device. If used incorrectly, it remarkably reduces
the efficacy of the drug and, consequently, the patient’s
compliance. For the treatment of COPD, the most
commonly used and preferred inhalers are DPI
(dry powder inhalers) [21]. The table below offers
an overview of some of the features of inhalers.
Each COPD medication comes with a dedicated
device. Indacaterol and glycopyrronium are
administered via Breezhaler (a low-resistance,
single-dose DPI), tiotropium via Handihaler
(single-dose DPI) or Respimat (soft inhaler), while
Aclidinium, Salmetorol/fluticasone, and formetorol/
budesonide via multi-dose DPI’s (Genuair, Diskus,
Turbohaler, respectively) (Table 2) [22].
As far as the inherent characteristics of inhalers are
concerned, it should always be kept in mind that in
the most severe stages of the disease, the inhaler
may fail to activate due to an inappropriate peak
inspiratory flow, which would prevent an effective
dose of drug from reaching the lungs [23]. The flow
level achieved depends on the lower resistance that
every device makes to the air flow during inhalationber of daily administrations
LABA/LAMA LABA/ICS
Indacaterol/Glicopirronium Vilanterol/Fluticasone
Vilanterol/Umeclidinium
Olodaterol/Tiotropium
Formaterol/Aclidinium Salmeterol/Fluticasone
Formaterol/Budesonide
de available soon.
Table 2 Active ingredients available on the market with their related device and dose
Breezhaler® Handihaler® Respimat® Genuair® Diskus® Turbohaler®
Active
ingredient
Indacaterol and
Glycopyrronium
Tiotropium
bromide
Tiotropium
bromide
Aclidinium
bromide
Salmeterol/fluticasone Formoterol/budesonide
Dose in a
capsule
150μg/300μg INDA 18μg 2,5μg 400μg6 50μg SAL 400μg BUD
50μg GLICO 100/250/500μg FP7 12μg FORM8
Delivered dose 120μg/240μg INDA 10μg9 2,5μg 375μg6 45μg SAL 320μg BUD
44μg GLICO 90/225/450μg FP10 9μg FORM8
Type of device SD-DPI SD-DPI Soft-inhaler MD-DPI MD-DPI MD-DPI
®, trademark.
Tabl
Intra-
depo
FPF
Intern
resist
FPF, F
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resistance of the different devices shows that Breezhaler
and Diskus have a lower internal resistance of 2.2 and
2.7 [x10−2 kPa½ L−1min], respectively, while such value
is higher for Handihaler, Genuair and Turbohaler, equal
respectively to 5.1, 3.5, 3.4 [x10−2 kPa½ L−1min] [24].
The different air-flow resistance levels offered by the
different devices imply different responses to the
inspiratory effort with the same level of flow. It is
also important that, also at a low flow, the drug
releases a suitable quantity of fine particles in
order to guarantee a homogeneous distribution in
the small airways. A comparison of the values of
such fraction (FPF) shows that Breezhaler, Respimat,
and Turbohaler release over 40% of the product in
fine particles, while Genuair and Handihaler release
30% and 9,8% respectively, and Diskus 14%-24%
(Table 3) [25,26].As it has been anticipated above, the device through
which the active ingredient is released by inhalation and
its technical characteristics play a crucial role and may
depend on several different factors, but compliance with
the medical treatment is equally important. In this respect,
the ability to check - on a gustatory, auditory, and espe-
cially visual level - the actual inhalation of the product -
for instance through transparent capsules (Breezhaler)
or by means of a color change in a window (Genuair) -
may be an important factor in increasing the patient’s
compliance, and may also generate some sort of addi-
tive effect to a specific active ingredient due to the fact
that the patient is sure that the daily dose was actually
delivered (placebo-like effect) (Table 4) [27].e 3 Inherent characteristics of the devices affecting prod
Breezhaler® Handihaler® Respimat®
thoracic
sition
39%14 22%14 52%15
42.6% 9.8% 66%18
al
ance
2.2x10−2kPa½ L
−1min 5.1x10−2kPa½ L
−1min Not applicab
ine particle fraction; ®, trademark.Overall, this data shows that not all devices are the
same and that the choice of the device may affect the
success rate of the therapy as much as the choice of
the active ingredient.
The consequences of non-adherence
Non-compliance with the prescribed medical therapy
has a number of negative consequences (Table 5).
Of course, the most severe factor of such conse-
quences is the increased risk of a poor clinical outcome,
although the economic impact also plays an important
role. In this respect, it should be pointed out that, in the
past few years, the growing use of active ingredients be-
longing to the LABA and LAMA classes led to a signifi-
cant improvement in survival after hospitalization due to
relapses (data from a Spanish study regarding two cohorts
of patients examined after 7 years in the 1996–1997 and
2003–2004 two-year periods), and that a mere 5% im-
provement in PDC (Proportion of Days Covered) may
reduce costs incurred into for examinations delivered
in hospital (−2.6%), day hospital (−2%), and Emergency
Room (−1.8%) settings [29].
Considering that, in Italy, failure to use inhaled medica-
tions for chronic respiratory diseases, or wrong use thereof,
leads to a 20% increase in the risk of hospitalization and to
a 50% increase in health-care expenditure for overall dir-
ect/indirect costs, which amount to €14 billion/year, of
which €9 billion are for COPD alone (with an estimated
per capita cost of €2,723), the extent of the problem is
easily understood [30].
In light of the facts outlined above, there is a clear need
to raise awareness among the local authorities “(Payor)”
as to the fact that the choice of an expensive treatment,uct delivery
Genuair® Diskus® Turbohaler®
30%16 8-14%17 25-35%17
36,5% 14-24%17 44-46%17
le 3.5x10−2kPa½ L
−1min 2.7x10−2 kPa½ L
−1min 3.4 x10−2kPa½ L
−1min
Figure 3 Resistance to air flow recorded with the main devices.
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not only aimed at improving personal wellbeing, but also
at reducing the overall expenditure.
Patient identification and compliance evaluation
It appears crucial to identify those COPD patients who
are “poorly or not at all compliant with their treatment,”
as if they were a separate clinical phenotype, so as to give
these patients the correct indications according to their
individual characteristics.
One or more of the following characteristics contribute
to defining the profile of non-adherent patients: they are
very old, never quit smoking, suffer from mild-moderate
COPD, take several different medications, live alone,
are depressed, have limited economic resources, show
cognitive/cultural deficits, have poor trust in physicians
and medications, do not realize the gravity of the dis-
ease or don’t want to see themselves as such, justify or
hide their symptoms, are reluctant to follow long-term
therapies, are well documented on their disease and know
that they need to take specific medications but do not take
any action and criticize any kind of pharmacological
option (evolved inactivity), and sometimes may not under-
stand the Italian language [31].
In order to evaluate adherence to the medical therapy,
several methods were proposed, the most effective of which
turned out to be self-reports, i.e. simple, brief question-
naires (e.g. Morisky test [32]) that provide a clear overview
of the respondents’ degree of compliance with their medical
therapy.Table 4 Different modalities used in different devices to chec
Breezhaler® Handihaler® Re
Auditory certainty YES NO NO
Gustatory certainty YES YES NO
Visual certainty YES (capsule empty) NO In
®, trademark.To increase the likelihood of quickly identifying non-
compliant patients, it may be useful to administer (for
example, in the waiting room before an examination) a
simple questionnaire including some specific items allow-
ing to identify the patient’s key characteristics [33].
Depending on the answers, patients who do not comply
with their pharmacological treatment may be classified as
belonging to one of the following 6 phenotypes: 1) patients
who consider the treatment too complex, 2) patients with
wrong beliefs, 3) patients who are not aware of the im-
portance to follow their prescriptions, 4) patients who
doubt the efficacy of their medications, 5) patients who
are poorly attentive, and 6) patients who believe that
the efforts required to comply with the therapy over-
weigh the benefits of the therapy itself. Later on, other
evaluations follow up to this initial assessment during
treatment so as to investigate the reasons underlying
any failure to comply with the therapy: wrong interpret-
ation, forgetfulness, skepticism, unconscious reasons
(denial of the problem, the drug reminds the patients of
their disease), administration route, adverse events, fear
of addiction, belief that the disease was finally cured, costs.
At this point, two homogeneous areas can be identified,
each including indicators that can be correlated with the
risk of poor adherence. The first area is geared towards
assessing personal/family-related risk situations and the
relationship with medications in general, while the second
one is aimed at defining the risks of poor adherence which
are directly linked to the relationship that COPD patients
already under treatment have with inhaled medications.k that the product was actually delivered
spimat® Genuair® Diskus® Turbohaler®
YES NO NO
NO NO NO
direct (Plume) Indirect (window) NO NO
Table 5 Negative consequences of non-adherence
– Poor control of symptoms
– Worsening of the quality of life
– Increasing number of relapses and more frequent need for health-
care services (which account for 35-45% of the disease-related costs)
– Higher mortality rate (2–3 times higher than in patients showing
good compliance – 26.4% vs. 11.3% according to a sub-analysis
made in the TORCH study [28]
– Increase in health-care expenditure.
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administered to naive patients for the identification of
their phenotype
In order to find out whether a patient will be compliant
with the physician’s prescription, a simple, quick ques-
tionnaire with only 6 questions can be administered to
naive patients in the waiting room before they are seen
by a doctor, which might be even more effective if it
were shared with Primary Care Medical Centers since it
is not limited to the category of inhaled drugs [10]. The
rationale behind the selection of such 6 questions is the
result of the following considerations: several studies
showed that patients’ compliance is inversely proportional
to the number of administrations (Question 1), living with
a family member could make it more likely for the pa-
tients to remember taking their medications (Question 2),
worries, physical disorders and poor compliance with the
medical examination schedule have a negative impact on
adherence (Questions 3, 4, and 6), the patients’ opinion on
inhaled medications is reflected on their consistent use
(Question 5) [34]. See Additional file 1.
Questionnaires for patients who are already under
treatment aimed at confirming their adherence status
and phenotype
The proposal of this questionnaire is to asses of non-
adherence in COPD patients with inhaled medication.
Here again, the indicators are gathered in a short ques-
tionnaire designed to be administered to patients who are
already under treatment, during their follow up examina-
tions. Based on few, simple questions, this questionnaire
may help pulmonologists to identify compliant, poorly
compliant, or non-compliant patients, and consequently
to take the necessary measures.
The proposed reference questionnaire is again the
Morisky scale [32], in a modified version with 3 specific
questions on inhaled therapies. See Additional file 2.
Suggestions for possible solutions
It should not be underestimated that compliance with
therapeutic choices is an indicator of quality of care, and
some organizations are already planning to use this aspect
through specific indicators (e.g. Centers for Medicare
and Medicaid Services Five-Star Quality Rating System)because of its high impact on the quality of life and on
health-care policies. The strategies for increasing adher-
ence that were most frequently quoted in a survey con-
ducted among pulmonologists were: to provide clear,
simple information on therapy schemes, and to identify
markers of non-compliance and defined clusters [35].
Once the risk of non-compliance is identified, the
possible corrective actions might be:
– To engage patients in the therapeutic strategy and
provide them with information on how to manage
difficulties
– To facilitate continuity in the delivery of health-care
services by the organization or specialists
– To treat comorbidities, especially depression and
anxiety
– To offer near-term follow up examinations to patients
at high risk of non-compliance
– To increase interactions between specialists and
general practitioners
– To disseminate technical data sheets on inhaled
medications in the most commonly spoken languages.
Another factor that should be taken into due consider-
ation, since it turned out to have a significant impact on
adherence to the prescribed therapy, is the selection of the
device, whose characteristics should be as close as possible
to those of an “ideal inhaler”:
– Dose reproducibility
– Operation under low flow peaks
– Lowest resistance to inhalation
– High release of fine particles
– Ability to check that the product was actually delivered.
In essence, four possible types of measures can be taken,
namely: prescription-related (simplification of administra-
tion and dosage of the medications), educational, behav-
ioral, and complex combined measures (combination of
two or more actions).
However, it is unquestionable that compliance with a
therapeutic regimen will improve if the patients are able
to perceive the severity of their disease and the benefits
of their treatment, if they become aware of being at risk
of exacerbations/complications, if they establish a good
relationship with their physician, and feel able to do what
the therapeutic regimen requires so as to develop a good
sense of self-efficacy and of locus of control.
Moreover, an important role in improving compliance
could be played by nurses, who can be put in charge of
conducting interviews with the patients before and during
treatment in order to motivate them - especially if
they are anxious and/or depressed - to adhere to their
prescriptions [36].
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In an age of evidence-based medicine, all efforts aimed
at reaching a higher level of quality in health care have
always been directed towards implementing educational
programs targeted to physicians so as to provide correct
pharmacological prescriptions with unquestionable,
proven efficacy, as demonstrated in large clinical trials
regarding outcome, quality of life, and prognostic indica-
tors. On the other hand, over the years, far less emphasis
has been put onto the actual compliance with the pre-
scribed medications, which is often considered to be ex-
clusively under the patient’s responsibility.
While it is clear that adherence in COPD is a critical
issue, and improving it will certainly take time and re-
quire major efforts, it is also obvious that raising aware-
ness of the disease and improving cooperation among
specialists, general practitioners, health-care profes-
sionals, and patients is the starting point at which this
evolution should immediately begin. Reaching the goal
of therapy adherence and success also depends on the
selection of the device. Each medication with its associ-
ated inhaler and its own active ingredient has different
characteristics in terms of internal resistance, intra-
thoracic deposition, mechanism to check that the prod-
uct was actually delivered, time and duration of action,
which may indeed foster good compliance with the ther-
apy and consequently maximize its efficacy [37].
This paper suggests the dissemination of two question-
naires among health-care professionals so that they can
check their usefulness in real-life scenarios, in addition,
it makes them available also to the scientific community
with a view to conduct further research projects aimed
at validating their actual efficacy.Additional files
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